Co-trimoxazole effect on human alveolar macrophages of AIDS patients

F. Luppi, M. Covi, G. Velluti, P. Spagnolo, L.M. Fabbri, L. Richeldi

Article ID: 6245
Vol 25, Issue 3, 2011
DOI: https://doi.org/10.54517/jbrha6245
Received: 9 October 2011; Accepted: 9 October 2011; Available online: 9 October 2011; Issue release: 9 October 2011

Abstract

Compelling evidence suggests that co-trimoxazole prophylaxis reduces mortality in HIV-infected patients, although it is unclear whether these effects are directly related to antimicrobial activities. We evaluated in vitro phagocytosis and killing of Staphylococcus aureus in alveolar macrophages (AM) obtained from AIDS patients who smoke, treated (n=19) or not treated (n=13) with co-trimoxazole, as compared to non-HIV-infected healthy smokers (n=15). Phagocytosis and killing of Staphylococcus aureus by AM obtained from non-co-trimoxazole treated AIDS patients were significantly lower compared to non-HIV-infected healthy smokers. In contrast, AIDS patients treated with co-trimoxazole prophylaxis showed phagocytosis and killing levels similar to those of healthy controls. These results might help to clarify the observed positive effect of co-trimoxazole on survival in HIV-infected patients


Keywords

acquired immunodeficiency syndrome;alveolar macrophages;co-trimoxazole;killing;phagocytosis


References

Supporting Agencies



Copyright (c) 2011 F. Luppi, M. Covi, G. Velluti, P. Spagnolo, L.M. Fabbri, L. Richeldi




This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).